Klaviyo, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

KVYO$20.43-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)

Series A Common Stock · Series B Common Stock · Treasury Stock · Additional Paid-In Capital · Total Stockholders’ Equity
Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Accumulated Deficit
Balance as of June 30, 2025	116,877,930	$117		182,757,254		$183		—	$—		$1,980,007			$(883,555)		$1,096,752
Issuance of common stock upon exercise of common stock options	—	—	160,120		—		—	—	267	—		267
Issuance of common stock upon vesting of restricted stock units	1,258,799	1	648,665		1		—	—	(2)	—		—
Issuance of common stock upon exercise of collaboration agreement warrants	—	—	344,383		—		—	—	3	—		3
Vested warrants related to collaboration agreement	—	—	—		—		—	—	8,100	—		8,100
Stock-based compensation expense	—	—	—		—		—	—	41,485	—		41,485
Tax withholdings on settlement of stock-based awards	(66,873)	—	(70,885)		—		—	—	(4,107)	—		(4,107)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	19,275,341	19		(19,275,341)		(19)		—	—		—		—		—
Net loss	—	—		—		—		—	—		—		(426)		(426)
Balance as of September 30, 2025	137,345,197	$137		164,564,196		$165		—	$—		$2,025,753			$(883,981)		$1,142,074
Balance as of June 30, 2026	131,203,855	$131		157,806,279		$158		20,479,864	$20		$1,843,479			$(876,764)		$967,024
Issuance of common stock upon exercise of common stock options	—	—	45,777		—		—	—	79	—		79
Issuance of common stock upon vesting of restricted stock units	1,647,192	2	169,224		—		—	—	(2)	—		—
Issuance of common stock upon exercise of collaboration agreement warrants	—	—	344,383		—		—	—	3	—		3
Vested warrants related to the collaboration agreement	—	—	—		—		—	—	8,100	—		8,100
Stock-based compensation expense	—	—	—		—		—	—	43,245	—		43,245
Tax withholdings on settlement of stock-based awards	(103,965)	—	(7,001)		—		—	—	(2,061)	—		(2,061)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	6,942,604	7	(6,942,604)		(7)		—	—	—	—		—
Share repurchases, inclusive of costs to acquire	(8,764,094)	(9)		—		—		8,764,094	9		(151,335)		—		(151,335)
Net income	—	—		—		—		—	—		—		704		704
Balance as of September 30, 2026	130,925,592	$131		151,416,058		$151		29,243,958	$29		$1,741,508			$(876,060)		$865,759

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (cont.)

Series A Common Stock · Series B Common Stock · Treasury Stock · Additional Paid-In Capital · Total Stockholders’ Equity
Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Accumulated Deficit
Balance as of January 1, 2025	88,956,301	$89	183,801,332	$184		—		$—		$1,878,899			$(845,185)		$1,033,987
Issuance of common stock upon exercise of common stock options	—	—	22,744,929	23	—		—		1,709		—		1,732
Issuance of common stock upon vesting of restricted stock units	3,357,508	3	2,104,777	3	—		—		(6)	—		—
Issuance of common stock upon exercise of collaboration agreement warrants	—	—	1,033,147	—	—		—		10		—		10
Issuance of common stock under the employee stock purchase plan	275,800	—	—	—	—		—		6,093		—		6,093
Vested warrants related to collaboration agreement	—	—	—	—	—		—		24,300		—		24,300
Stock-based compensation expense	—	—	—	—	—		—		127,803		—		127,803
Tax withholdings on settlement of stock-based awards	(183,532)	—	(180,869)	—	—		—		(13,055)		—		(13,055)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	44,939,120	45	(44,939,120)	(45)		—		—		—			—	—
Net loss	—	—	—	—		—		—		—			(38,796)		(38,796)
Balance as of September 30, 2025	137,345,197	$137	164,564,196	$165		—		$—		$2,025,753			$(883,981)		$1,142,074
Balance as of January 1, 2026	144,262,443	$144	159,899,668	$160		—		$—		$2,073,209			$(876,953)		$1,196,560
Issuance of common stock upon exercise of common stock options	—	—	874,401	1		—		—		876			—		877
Issuance of common stock upon vesting of restricted stock units	4,666,174	5	940,709	—		—		—		(6)			—		(1)
Issuance of common stock upon exercise of collaboration agreement warrants	—	—	1,033,147	1		—		—		9			—		10
Issuance of common stock under the employee stock purchase plan	309,821	—	—	—		—		—		3,978			—		3,978
Vested warrants related to the collaboration agreement	—	—	—	—		—		—		24,300			—		24,300
Stock-based compensation expense	—	—	—	—		—		—		138,342			—		138,342
Tax withholdings on settlement of stock-based awards	(304,983)	—	(95,772)	—		—		—		(6,940)			—		(6,940)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	11,236,095	11	(11,236,095)	(11)		—		—		—			—		—
Share repurchases, inclusive of costs to acquire	(29,243,958)	(29)	—	—		29,243,958		29		(492,260)			—		(492,260)
Net income	—	—	—	—		—		—		—			893		893
Balance as of September 30, 2026	130,925,592	$131	151,416,058	$151		29,243,958		$29		$1,741,508			$(876,060)		$865,759

The accompanying notes are an integral part of these condensed consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.